Virological tools to diagnose and monitor hepatitis C virus infection

Clinical Microbiology and Infection

Volumn 17, Issue 2, 2011, Pages 116-121

  Chevaliez, S ^a  

^a HENRI MONDOR HOSPITAL   (France)

Author keywords

Diagnosis; Hepatitis C virus (HCV); Real time PCR assays; Viral hepatitis; Virological tools

Indexed keywords

BOCEPREVIR; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PROTEINASE INHIBITOR; RIBAVIRIN; TELAPREVIR; VIRUS ANTIGEN; VIRUS RNA;

ACUTE HEPATITIS; ANTIBODY DETECTION; ANTIVIRAL THERAPY; DIAGNOSTIC KIT; DRUG CONTRAINDICATION; DRUG DOSE REGIMEN; DRUG INDICATION; DRUG MONITORING; ENZYME IMMUNOASSAY; ERADICATION THERAPY; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LOW DRUG DOSE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; RNA ANALYSIS; SEQUENCE ANALYSIS; TREATMENT DURATION; TREATMENT OUTCOME; VIRUS CORE; VIRUS DETECTION; VIRUS DIAGNOSIS; VIRUS GENOME; VIRUS LOAD; VIRUS RESISTANCE;

HEPATITIS C VIRUS;

EID: 78751624390     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2010.03418.x     Document Type: Review

References (40)

1. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005; 5: 558-567.
2. McHutchison JG et al. Peginterferon α2b or α2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009; 361: 580-593.
3. Pawlotsky JM. Therapeutic implications of hepatitis C virus resistance to antiviral drugs. Therap Adv Gastroenterol 2009; 2: 205-219.
4. Ge D et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401.
5. Suppiah V et al. IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy. Nat Genet 2009; 41: 1100-1104.
6. Tanaka Y et al. Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41: 1105-1109.
7. Busch MP et al. A new strategy for estimating risks of transfusion-transmitted viral infections based on rates of detection of recently infected donors. Transfusion 2005; 45: 254-264.
8. Hellstrom UB et al. Immunoglobulin M reactivity towards the immunologically active region sp75 of the core protein of hepatitis C virus (HCV) in chronic HCV infection. J Med Virol 1993; 39: 325-332.
9. Negro F et al. Lack of monomeric IgM anti-hepatitis C virus (HCV) core antibodies in patients with chronic HCV infection. J Virol Methods 1996; 60: 179-182.
10. Sagnelli E et al. Diagnosis of HCV related acute hepatitis by serial determination of IgM to HCV: a preliminary observation. J Biol Regul Homeost Agents 2003; 17: 207-210.
11. Sagnelli E et al. Diagnosis of hepatitis C virus related acute hepatitis by serial determination of IgM anti-HCV titres. J Hepatol 2005; 42: 646-651.
12. Coppola N et al. Anti-HCV IgG avidity index in acute hepatitis C. J Clin Virol 2007; 40: 110-115.
13. Coppola N et al. Improvement in the aetiological diagnosis of acute hepatitis C: a diagnostic protocol based on the anti-HCV-IgM titre and IgG Avidity Index. J Clin Virol 2009; 46: 222-229.
14. Bouvier-Alias M et al. Clinical utility of total HCV core antigen quantification: a new indirect marker of HCV replication. Hepatology 2002; 36: 211-218.
15. Park Y et al. New automated hepatitis C virus (HCV) core antigen assay as an alternative to real-time PCR for HCV RNA quantification. J Clin Microbiol 2010; 48: 2253-2256.
16. Ross RS et al. Analytical performance characteristics and clinical utility of a novel assay for total hepatitis C virus core antigen quantification. J Clin Microbiol 2010; 48: 1161-1168.
17. Moscato GA et al. Quantitative determination of hepatitis C core antigen in therapy monitoring for chronic hepatitis C. Intervirology 2010; 54: 61-65.
18. Miedouge M et al. Analytical evaluation of HCV core antigen and interest for HCV screening in haemodialysis patients. J Clin Virol ????; 48: 18-21.
19. Laperche S et al. Simultaneous detection of hepatitis C virus (HCV) core antigen and anti-HCV antibodies improves the early detection of HCV infection. J Clin Microbiol 2005; 43: 3877-3883.
20. Gish RG, Locarnini SA. Chronic hepatitis B: current testing strategies. Clin Gastroenterol Hepatol 2006; 4: 666-676.
21. Pawlotsky JM Use and interpretation of virological tests for hepatitis C. Hepatology 2002; 36 (5 suppl 1): S65-S73.
22. Chevaliez S et al. Overestimation and underestimation of hepatitis C virus RNA levels in a widely used real-time polymerase chain reaction-based method. Hepatology 2007; 46: 22-31.
23. Chevaliez S, Bouvier-Alias M, Pawlotsky JM. Performance of the Abbott m2000SP/m2000RT real-time polymerase chain reaction assay for hepatitis C virus RNA quantification. J Clin Microbiol 2010; 47: 1726-1732.
24. Chevaliez S et al. The Cobas AmpliPrep-Cobas TaqMan real-time polymerase chain reaction assay fails to detect hepatitis C virus RNA in highly viremic genotype 4 clinical samples. Hepatology 2009; 49: 1397-1398.
25. Chevaliez S et al. Underestimation of hepatitis C virus genotype 4 RNA levels by the Cobas Ampliprep/Cobas Taqman assay. Hepatology 2009; 50: 1681.
26. Sertoz RY et al. Comparison of sequence analysis and INNO-LiPA HBV DR line probe assay in patients with chronic hepatitis B. J Chemother 2005; 17: 514-520.
27. Bouchardeau F et al. Improvement of hepatitis C virus (HCV) genotype determination with the new version of the INNO-LiPA HCV assay. J Clin Microbiol 2007; 45: 1140-1145.
28. Chevaliez S et al. HCV genotype determination in clinical practice: weaknesses of assays based on the 5'noncoding region and improvement with the core-coding region. Hepatology 2007; 46(4 suppl 1): 839A.
29. Stelzl E et al. Determination of the hepatitis C virus subtype: comparison of sequencing and reverse hybridization assays. Clin Chem Lab Med 2007; 45: 167-170.
30. Verbeeck J et al. Evaluation of versant hepatitis C virus genotype assay (LiPA) 2.0. J Clin Microbiol 2008; 46: 1901-1906.
31. Hadziyannis SJ et al. Peginterferon-α2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346-355.
32. Lok AS et al. Antibody response to core, envelope and nonstructural hepatitis C virus antigens: comparison of immunocompetent and immunosuppressed patients. Hepatology 1993; 18: 497-502.
33. Thio CL et al. Screening for hepatitis C virus in human immunodeficiency virus-infected individuals. J Clin Microbiol 2000; 38: 575-577.
34. NIH Consensus Statement on Management of Hepatitis C: 2002. NIH Consens State Sci Statements 2002; 19: 1-46.
35. Diago M et al. Identifying hepatitis C virus genotype 2/3 patients who can receive a 16-week abbreviated course of peginterferon α2a (40KD) plus ribavirin. Hepatology 2010; 51: 1897-1903.
36. Moreno C et al. Shortened treatment duration in treatment-naive genotype 1 HCV patients with rapid virological response: a meta-analysis. J Hepatol 2010; 52: 25-31.
37. Berg T et al. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72weeks of peginterferon-α2a plus ribavirin. Gastroenterology 2006; 130: 1086-1097.
38. Ferenci P et al. Peginterferon α2a/ribavirin for 48 or 72weeks in hepatitis C genotypes 1 and 4 patients with slow virologic response. Gastroenterology. 2010; 138: 503-512, 512 e1.
39. Sanchez-Tapias JM et al. Peginterferon-α2a plus ribavirin for 48 versus 72weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. Gastroenterology 2006; 131: 451-460.
40. Swain MG et al. A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon α2a and ribavirin. Gastroenterology 2010; 139: 1593-1601.